



## **Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results**

April 29, 2019

DUBLIN, Ireland, April 29, 2019 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Wednesday, May 8, 2019, to provide a corporate update and discuss details of the Company's financial results for the first quarter ended March 31, 2019.

To access the conference call, investors are invited to dial (844) 388-0559 (U.S. and Canada) or (216) 562-0393 (international). The conference ID number is 3258059. A live audio webcast can be accessed by visiting the investor relations section of the Company's website, [www.avadel.com](http://www.avadel.com). A replay of the webcast will be archived on Avadel's website for 90 days following the event.

### **About Avadel Pharmaceuticals plc:**

Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a branded specialty pharmaceutical company. The Company's primary focus is on the development and potential FDA approval for FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. In addition, Avadel markets three sterile injectable drugs used in the hospital setting, which were developed under the Company's "unapproved marketed drug" (UMD) program. Avadel is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France. For more information, please visit [www.avadel.com](http://www.avadel.com).

### **Contacts: Michael F. Kanan**

**Chief Financial Officer**

Phone: (636) 449-1844

Email: [mkanan@avadel.com](mailto:mkanan@avadel.com)

**Alex Gray**

**Burns McClellan**

Phone: (212) 213-0006

Email: [agray@burnsmc.com](mailto:agray@burnsmc.com)



Source: Avadel Pharmaceuticals plc